Table 3.
Thiosemicarbazones do not induce changes in blood cytology (CBC) following treatment of KP02 tumor-bearing C57BL/6 mice.
| A.
| ||||
|---|---|---|---|---|
| Control | 7 | 1 | 2 | |
| WBC (10 3 /μL) | 7.8 ± 0.55 | 7.93 ± 1.35 | 5.75 ± 0.45 | 8.87 ± 0.63 |
| RBC (10 6 /μL) | 9.35 ± 0.11 | 8.63 ± 0.71 | 9.19 ± 0.15 | 9.94 ± 0.92 |
| HGB (g/dL) | 13.8 ± 0.1 | 12.9 ± 1.1 | 13.45 ± 0.05 | 14.9 ± 0.9 |
| PCV (%) | 47.5 ± 3 | 42.65 ± 2.85 | 45.45 ± 4.15 | 51 ± 3.8 |
| MCV (fL) | 50.7 ± 0.76 | 49.45 ± 0.75 | 49.5 ± 0.1 | 51.4 ± 0.9 |
| MCH (pg) | 14.8 ± 0.1 | 14.95 ± 0.05 | 14.65± 0.15 | 15 ± 0.5 |
| MCHC (%) | 29.13 ± 0.83 | 30.2 ± 0.6 | 29.6 ± 0.3 | 29.25 ± 0.45 |
| Platelets (10 3/μL) | 951.6 ± 86.3 | 865 ± 25 | 976.5 ± 81.5 | 854 ± 47 |
|
B. | ||||
| Control | 7 | 1 | 2 | |
| BUN (mg/dL) | 27.3 ± 2.66 | 29.5 ± 2.5 | 22 ± 2 | 21.5 ± 1.5 |
| Creatinine (mg/dL) | 0.33 ± 0.02 | 0.35 ± 0.12 | 0.31 ± 0.02 | 0.34± 0.1 |
| ALT (μ/L) | 54.3 ± 6.33 | 257 ± 27 | 95 ± 41 | 147.5 ± 86.5 |
| AST (μ/L) | 98.6 ± 0.05 | 573.5± 37.4 | 172 ± 11.2 | 416 ± 21.2 |
| Total Protein (g/dL) | 5.55 ± 0.15 | 5.5 ± 0.3 | 5.1 ± 0.1 | 5.75 ± 0.35 |
| Glucose (mg/dL) | 168 ± 3.3 | 309 ± 4 | 285 ± 24.5 | 288.5 ± 26.5 |
(A) Blood cytology analysis of C57BL/6 mice (n = 3 mice/group) treated with thiosemicarbazone 7 (750nmol/100μL), σ2 ligands 1 and 2 (1500nmol/100 μL) and vehicle (control) for 2 weeks. The differences in complete blood count laboratory values between the two groups are not statistically significant, p > 0.05.
(B) Biochemical analysis of C57BL/6 mice (n = 3 mice/group) treated with thiosemicarbazone 7 (750nmol/100μL), σ2 ligands 1 and 2 (1500nmol/100 μL) and vehicle (control) for 2 weeks. The differences in serum chemistries between the groups are not statistically significant, p > 0.05.